HCMC – Nanogen Pharmaceutical Biotechnology JSC, the developer of Vietnam’s first Covid-19 vaccine candidate Nano Covax, has signed a non-disclosure agreement to transfer the vaccine production technology to India’s Vekaria Healthcare LLP.
Nanogen general director Ho Nhan on August 10 said that further steps would begin this month, the local media reported.
The Vietnamese Embassy in India on the same day also announced the signing ceremony of the agreement held on August 8.
Pham Sanh Chau, Vietnamese Ambassador to India, said the cooperation between the two companies is important in the context that the pandemic has been raging in India, Vietnam and many other parts of the world. The early trial, production and distribution of Nano Covax on a large scale will contribute to combating the pandemic.
The embassy cited a representative of Vekaria Healthcare Company as saying Nano Covax has been researched and developed using the recombinant protein technology and initial reports have shown it is promising.
Nanogen has researched Nano Covax since mid-2020 and started the human trial of the vaccine on December 17, 2020.
The third trial phase of the vaccine is being conducted on 13,000 volunteers.
Nhan said in June that Nanogen’s capacity is 8-12 million doses per month. The company is upgrading its production lines to produce 30-50 million doses per month by October, 50 million by October and 100 million by 2022.